文献速递其他结缔组织病

清髓性自体造血干细胞移植使系统性硬化症患者的B细胞库重置为更初始的状态

Myeloablative autologous haematopoietic stem cell transplantation resets the B cell repertoire to a more naïve state in patients with systemic sclerosis.
PubMed 文献 · Ann Rheum Dis · 2022-10-14

该研究对SCOT试验中弥漫性皮肤型系统性硬化症患者的外周血免疫球蛋白重链(IGH)库进行测序,发现清髓性自体造血干细胞移植与低突变率IgM同型抗体持续增加、IGH库克隆性表达减少相关,且IGHV5-51使用不足在移植后正常化而环磷酰胺未出现此变化。

要点

  • 清髓性自体造血干细胞移植后低突变率IgM同型抗体持续增加。
  • 移植后IGH库克隆性表达减少。
  • dcSSc患者IGHV5-51使用不足,移植后正常化而环磷酰胺未正常化。

核心结论

  • 清髓性自体造血干细胞移植将IGH库重置为以表达IgM的B细胞为特征的更初始状态,可能为消除致病性B细胞提供机制,从而有助于解释HSCT优于CYC治疗dcSSc的获益。

研究设计与样本

  • 对SCOT试验中入组的弥漫性皮肤型系统性硬化症患者进行外周血免疫球蛋白重链(IGH)库测序。

主要发现

  • 清髓性自体造血干细胞移植与低突变率IgM同型抗体持续增加相关。
  • 清髓性自体造血干细胞移植后IGH库克隆性表达减少。
  • dcSSc患者存在IGHV5-51使用不足,清髓性自体造血干细胞移植后使用正常化,而环磷酰胺治疗未正常化。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Myeloablative autologous haematopoietic stem cell transplant (HSCT) was recently demonstrated to provide significant benefit over cyclophosphamide (CYC) in the treatment of diffuse cutaneous systemic sclerosis (dcSSc) in the Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial. As dysregulation of the B cell compartment has previously been described in dcSSc, we sought to gain insight into the effects of myeloablative autologous HSCT as compared with CYC. METHODS: We sequenced the peripheral blood immunoglobulin heavy chain (IGH) repertoires in patients with dcSSc enrolled in the SCOT trial. RESULTS: Myeloablative autologous HSCT was associated with a sustained increase in IgM isotype antibodies bearing a low mutation rate. Clonal expression was reduced in IGH repertoires following myeloablative autologous HSCT. Additionally, we identified a underusage of immunoglobulin heavy chain V gene 5-51 in patients with dcSSc, and usage normalised following myeloablative autologous HSCT but not CYC treatment. CONCLUSIONS: Together, these findings suggest that myeloablative autologous HSCT resets the IGH repertoire to a more naïve state characterised by IgM-expressing B cells, providing a possible mechanism for the elimination of pathogenic B cells that may contribute to the benefit of HSCT over CYC in the treatment of dcSSc.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Adamska JZ, Zia A, Bloom MS, et al. Myeloablative autologous haematopoietic stem cell transplantation resets the B cell repertoire to a more naïve state in patients with systemic sclerosis. Ann Rheum Dis. 2022. PMID: 36241361. doi:10.1136/ard-2021-221925

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。